Kedrion Biopharma, a global player in plasma-derived therapies, has announced a major investment plan in Tuscany with the construction of a new production site in Bolognana, in the municipality of Gallicano (province of Lucca). The facility, which will complement the company’s existing operations in the area, represents an investment of approximately €150 million and is expected to generate around 100 new jobs.
The announcement was made by CEO Ugo Di Francesco, who confirmed that the new plant will double Kedrion’s local production capacity, reaching two million liters of plasma fractionation. Construction is set to begin soon, with the facility expected to enter production between late 2028 and early 2029, pending regulatory approvals.
In addition, the company is preparing to activate another production site in Castelvecchio Pascoli, also in the Lucca area, where Kedrion plans to manufacture next-generation immunoglobulins such as KIG10, developed in-house. Final approval from the U.S. FDA is anticipated by September 2025.
Kedrion, which recorded €1.578 billion in revenues in 2024 (+10% year-over-year) and an adjusted EBITDA of €279 million (+20%), continues to expand its global footprint with seven manufacturing plants across Italy, the UK, the US, Hungary, and Canada.
Following the 2022 merger with UK-based BPL and the entry of investment fund Permira as majority shareholder, the company has entered a new phase of growth and financial stability. Permira’s involvement has enabled Kedrion to overcome post-pandemic challenges and focus once again on strategic investments. In 2024 alone, over €140 million was allocated to production, clinical research, and digitalization, with even higher investments expected in 2025.
Looking ahead, Kedrion plans to continue expanding its international market presence while proactively addressing potential trade risks such as future tariffs. The group remains optimistic about maintaining its growth trajectory and improving profitability in the coming year.
